More extensive assay development and clinical validation (phases 2–4) are also needed for broader biomarkers such as NfL, GFAP, and markers of seeding-competent proteinopathies like TDP-43 and tau (Fig. 2) [154]. Here, TARDBP is linked to proteostasis deficiencies.